The biomarker revolution: A step toward personalized medicine

Personalized Medicine

Volumn 5, Issue 6, 2008, Pages 553-556

  Bobbefoy, Jean Yves ^a  

^a TRANSGENE S A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CALCITONIN; CHOLESTEROL; CHORIONIC GONADOTROPIN; GLUCOSE; PROSTATE SPECIFIC ANTIGEN; VIRUS ANTIGEN;

BLOOD PRESSURE; BODY TEMPERATURE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHORIOCARCINOMA; DIABETES MELLITUS; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; EDITORIAL; FEVER; GENOMICS; GLUCOSE BLOOD LEVEL; GLYCOBIOLOGY; HEPATITIS; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; ONCOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TESTIS CARCINOMA; THYROID CARCINOMA; TRANSCRIPTOMICS;

EID: 57749207452     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.6.553     Document Type: Editorial

References (2)

1. Biomarker Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
2. De Gruttola VG, Clax P, DeMets DL et al.: Considerations in the evaluation of surrogate endpoints in clinical trials, summary of a National Institutes of Health workshop. Control Clin. Trials 22(5), 485-502 (2001).